These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 23704316)

  • 1. Mycophenolate mofetil in multiple sclerosis: a multicentre retrospective study on 344 patients.
    Michel L; Vukusic S; De Seze J; Ducray F; Ongagna JC; Lefrère F; Jacq-Foucher M; Confavreux C; Wiertlewski S; Laplaud DA
    J Neurol Neurosurg Psychiatry; 2014 Mar; 85(3):279-83. PubMed ID: 23704316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mycophenolate mofetil in the treatment of multiple sclerosis: a preliminary report.
    Pandit L; Mustafa S; Malli C; D'Cunha A
    Neurol India; 2014; 62(6):646-8. PubMed ID: 25591678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of mycophenolate mofetil in progressive multiple sclerosis patients.
    Fakih R; Matiello M; Chitnis T; Stankiewicz JM
    J Neurol; 2018 Nov; 265(11):2688-2694. PubMed ID: 30203314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of mycophenolate mofetil therapy in neuromyelitis optica spectrum disorders: a systematic review and meta-analysis.
    Songwisit S; Kosiyakul P; Jitprapaikulsan J; Prayoonwiwat N; Ungprasert P; Siritho S
    Sci Rep; 2020 Oct; 10(1):16727. PubMed ID: 33028926
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and cyclophosphamide among patients with neuromyelitis optica spectrum disorder: A prospective cohort study.
    Xu Y; Wang Q; Ren HT; Qiao L; Zhang Y; Fei YY; Zhao Y; Cui LY
    J Neurol Sci; 2016 Nov; 370():224-228. PubMed ID: 27772764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Efficacy and Tolerability of Mycophenolate Mofetil in Treating Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder in Western China.
    Chen H; Zhang Y; Shi Z; Feng H; Yao S; Xie J; Zhou H
    Clin Neuropharmacol; 2016; 39(2):81-7. PubMed ID: 26818042
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mycophenolate mofetil is an effective and safe option for the management of systemic sclerosis-associated interstitial lung disease: results from the Australian Scleroderma Cohort Study.
    Owen C; Ngian GS; Elford K; Moore O; Stevens W; Nikpour M; Rabusa C; Proudman S; Roddy J; Zochling J; Hill C; Sturgess A; Tymms K; Youssef P; Sahhar J
    Clin Exp Rheumatol; 2016; 34 Suppl 100(5):170-176. PubMed ID: 27049330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mycophenolate mofetil in multiple sclerosis.
    Frohman EM; Brannon K; Racke MK; Hawker K
    Clin Neuropharmacol; 2004; 27(2):80-3. PubMed ID: 15252268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mycophenolate mofetil for the treatment of scleritis.
    Sen HN; Suhler EB; Al-Khatib SQ; Djalilian AR; Nussenblatt RB; Buggage RR
    Ophthalmology; 2003 Sep; 110(9):1750-5. PubMed ID: 13129873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mycophenolate mofetil versus cyclophosphamide for inducing remission of ANCA vasculitis with moderate renal involvement.
    Hu W; Liu C; Xie H; Chen H; Liu Z; Li L
    Nephrol Dial Transplant; 2008 Apr; 23(4):1307-12. PubMed ID: 18065810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quality of life comparison between corticosteroid- and-mycofenolate mofetil and corticosteroid- and-oral cyclophosphamide in the treatment of severe lupus nephritis.
    Tse KC; Tang CS; Lio WI; Lam MF; Chan TM
    Lupus; 2006; 15(6):371-9. PubMed ID: 16830884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mycophenolate mofetil in diffuse cutaneous systemic sclerosis--a retrospective analysis.
    Nihtyanova SI; Brough GM; Black CM; Denton CP
    Rheumatology (Oxford); 2007 Mar; 46(3):442-5. PubMed ID: 16899504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is mycophenolate mofetil an effective alternative in azathioprine-intolerant patients with chronic active Crohn's disease?
    Miehsler W; Reinisch W; Moser G; Gangl A; Vogelsang H
    Am J Gastroenterol; 2001 Mar; 96(3):782-7. PubMed ID: 11280551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delayed severe pneumonia in mycophenolate mofetil-treated patients with IgA nephropathy.
    Lv J; Zhang H; Cui Z; Su T; Zhang Y; Wang H
    Nephrol Dial Transplant; 2008 Sep; 23(9):2868-72. PubMed ID: 18463325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Mycophenolate mofetil in treatment of childhood nephrotic syndrome--preliminary report].
    Kwinta-Rybicka J; Wilkosz K; Wierzchowska-Słowiacze EK; Ogarek I; Moczulska A; Stec Z; Pełkowska A; Sancewicz-Pach K; Pietrzyk JA
    Przegl Lek; 2006; 63 Suppl 3():44-8. PubMed ID: 16898486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mycophenolate mofetil is a highly effective and safe immunosuppressive agent for the treatment of uveitis : a retrospective analysis of 106 patients.
    Siepmann K; Huber M; Stübiger N; Deuter C; Zierhut M
    Graefes Arch Clin Exp Ophthalmol; 2006 Jul; 244(7):788-94. PubMed ID: 16163494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term efficacy and tolerability of mycophenolate mofetil therapy in diffuse scleroderma skin disease.
    Boulos D; Ngian GS; Rajadurai A; Elford K; Stevens W; Proudman S; Owen C; Roddy J; Nikpour M; Youssef P; Hill C; Sahhar J
    Int J Rheum Dis; 2017 Apr; 20(4):481-488. PubMed ID: 28337853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy and safety of mycophenolate mofetil in Thai neuromyelitis optica spectrum disorder patients.
    Pathomrattanapiban C; Tisavipat N; Jitprapaikulsan J; Prayoonwiwat N; Rattanathamsakul N; Siritho S
    Mult Scler Relat Disord; 2022 Jul; 63():103882. PubMed ID: 35598463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of worsening multiple sclerosis with mitoxantrone: a review.
    Fox EJ
    Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of cyclophosphamide and mycophenolate on end-stage renal disease and death of lupus nephritis.
    Koo HS; Kim YC; Lee SW; Kim DK; Oh KH; Joo KW; Kim YS; Ahn C; Han JS; Kim S; Chin HJ
    Lupus; 2011 Nov; 20(13):1442-9. PubMed ID: 21951944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.